Background/Aims Galectin-3 plays a key pathogenic role in cardiac hypertrophy and heart failure. The present study aimed to investigate the effects of galectin-3 on cardiomyopathy – related factors and cardiac contractility in a rat model of cirrhotic cardiomyopathy.
Methods Rats were divided into two sets, one for a functional study, the other for cardiac contractile-related protein evaluation. There were four groups in each set: sham operated and sham plus N-acetyllactosamine (N-Lac, a galectin-3 inhibitor; 5 mg/kg); bile duct ligated (BDL) and BDL plus N-Lac. Four weeks after surgery, ventricular level of galectin-3, collagen I and III ratio, tumor necrosis factor alpha (TNFα), and brain natriuretic peptide (BNP) were measured either by Western blots or immunohistochemistry or enzyme-linked immunosorbent assay. Blood pressure was measured by polygraph recorder. Cardiomyocyte contractility was measured by inverted microscopy.
Results Galectin-3 and collagen I/III ratio were significantly increased in cirrhotic hearts. TNFα and BNP were significantly increased in BDL serum and heart compared with sham controls. Galectin-3 inhibitor significantly decreased galectin-3, TNFα, and BNP in cirrhotic hearts but not in sham controls. N-Lac also significantly improved the blood pressure, and systolic and diastolic cardiomyocyte contractility in cirrhotic rats but had no effect on sham controls.
Conclusion Increased galectin-3 in the cirrhotic heart significantly inhibited contractility via TNFα. Inhibition of galectin-3 decreased the cardiac content of TNFα and BNP and reversed the decreased blood pressure and depressed contractility in the cirrhotic heart. Galectin-3 appears to play a pathogenic role in cirrhotic cardiomyopathy.
Citations
Citations to this article as recorded by
Apoptosis in Cardiac Conditions Including Cirrhotic Cardiomyopathy Fengxue Yu, Dae Gon Ryu, Ki Tae Yoon, Hongqun Liu, Samuel S. Lee International Journal of Molecular Sciences.2025; 26(13): 6423. CrossRef
Cirrhotic Cardiomyopathy: Bridging Hepatic and Cardiac Pathophysiology in the Modern Era Dragoș Lupu, Camelia Cornelia Scârneciu, Diana Țînț, Cristina Tudoran Journal of Clinical Medicine.2025; 14(17): 5993. CrossRef
Galectin-3: A Multitasking Protein Linking Cardiovascular Diseases, Immune Disorders and Beyond Mariarosaria Morello, Gisella Titolo, Saverio D’Elia, Silvia Caiazza, Ettore Luisi, Achille Solimene, Chiara Serpico, Andrea Morello, Francesco Natale, Paolo Golino, Plinio Cirillo, Giovanni Cimmino Targets.2025; 3(4): 34. CrossRef
Galectin-3 as a therapeutic target in pulmonary hypertension: Molecular mechanisms, drug development directions, and emerging clinical applications Antonín Sedlář, Pavla Bojarová, František Kolář, Vladimír Křen, Lucie Bačáková Biomedicine & Pharmacotherapy.2025; 193: 118756. CrossRef
Cardiomyopathy in cirrhosis: From pathophysiology to clinical care Hongqun Liu, Jwan A. Naser, Grace Lin, Samuel S. Lee JHEP Reports.2024; 6(1): 100911. CrossRef
Cirrhotic cardiomyopathy: Pathogenesis, clinical features, diagnosis, treatment and prognosis Francisca Almeida, Alexandra Sousa Revista Portuguesa de Cardiologia.2024; 43(4): 203. CrossRef
Therapies for Cirrhotic Cardiomyopathy: Current Perspectives and Future Possibilities Hongqun Liu, Daegon Ryu, Sangyoun Hwang, Samuel S. Lee International Journal of Molecular Sciences.2024; 25(11): 5849. CrossRef
Role of Galectin in Cardiovascular Conditions including Cirrhotic Cardiomyopathy Hongqun Liu, Sang-Youn Hwang, Samuel S. Lee Pharmaceuticals.2023; 16(7): 978. CrossRef
Chenodeoxycholic Acid Improves Embryo Implantation and Metabolic Health through Modulating Gut Microbiota–Host Metabolites Interaction during Early Pregnancy Meixia Chen, Ying Zhao, Haifeng Ji, Lu Li, Hui Liu, Sixin Wang, Dongyan Zhang, Jingdong Yin, Jing Wang, Xin Zhang Antioxidants.2023; 13(1): 8. CrossRef
Temporal profile of cerebrospinal fluid galactin-3 and associated cytokine responses after severe traumatic brain injury in patients: a retrospective study Melisa Cetin, Ping Yip, Zhou-Hao Liu Future Healthcare Journal.2023; 10: S18. CrossRef
Temporal profile of cerebrospinal fluid galactin-3 and associated cytokine responses after severe traumatic brain injury in patients: a retrospective study Melisa Cetin, Ping Yip, Wing Sze Leung, Zhou-Hao Liu Clinical Medicine.2023; 23(6): 81. CrossRef
Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy Hongqun Liu, Henry H. Nguyen, Ki Tae Yoon, Samuel S. Lee Frontiers in Network Physiology.2022;[Epub] CrossRef
Collagen-binding fibroblast growth factor ameliorates liver fibrosis in murine bile duct ligation injury Qiangqiang Shi, Susu Wei, Zhi Chao Li, Jing Xu, Yaxin Li, Chuanlong Guo, Xianggen Wu, Chunying Shi, Guohu Di Journal of Biomaterials Applications.2022; 37(5): 918. CrossRef
Nonselective beta-adrenergic blocker (NSBB) therapy for the prevention of initial and recurrent gastrointestinal bleeding in cirrhotic patients with gastroesophageal varices has been used for the past four decades. NSBB therapy is considered the cornerstone of treatment for varices, and has become the standard of care. However, a 2010 study from the group that pioneered β-blocker therapy suggested a detrimental effect of NSBBs in decompensated cirrhosis, especially in patients with refractory ascites. Since then, numerous additional studies have incompletely resolved whether NSBBs are deleterious, although more recent evidence weighs against a harmful effect. The possibility of a “therapeutic window” has also been raised. We aimed to review the literature to analyze the pros and cons of using NSBBs in patients with cirrhosis, not only with respect to bleeding or mortality but also to other potential benefits and risks. β-blockers are highly effective in preventing first bleeding and recurrent bleeding. Furthermore, NSBBs improve congestion/ischemia of the gut mucosa, decrease intestinal permeability, and therefore indirectly alleviate systemic inflammation. β-blockers shorten the electrocardiographic prolonged QTc interval and may also decrease the incidence of hepatocellular carcinoma. On the other hand, the possibility of deleterious effects in cirrhosis has not been completely eliminated. NSBBs may be associated with an increased risk of portal vein thrombosis, although this could be correlational artifact. Overall, we conclude that β-blockers in cirrhosis are much more of a friend than enemy.
Citations
Citations to this article as recorded by
Potential therapies for acute‐on‐chronic liver failure Maura A. Morrison, Florent Artru, Francesca M. Trovato, Evangelos Triantafyllou, Mark J. McPhail Liver International.2025;[Epub] CrossRef
Advancements of direct oral anticoagulants in cirrhotic individuals with portal vein thrombosis Zhiqian Liu, Xiying Yang, Haitao Jiang, Rui Xie, Hong Wang Clinics and Research in Hepatology and Gastroenterology.2025; 49(4): 102553. CrossRef
Cirrhotic Cardiomyopathy: Bridging Hepatic and Cardiac Pathophysiology in the Modern Era Dragoș Lupu, Camelia Cornelia Scârneciu, Diana Țînț, Cristina Tudoran Journal of Clinical Medicine.2025; 14(17): 5993. CrossRef
Principles of Non-selective Beta-blocker Usage for Cirrhosis-associated Complications Daisy K. Maclaine, Kosha J. Mehta SN Comprehensive Clinical Medicine.2025;[Epub] CrossRef
Cardiomyopathy in cirrhosis: From pathophysiology to clinical care Hongqun Liu, Jwan A. Naser, Grace Lin, Samuel S. Lee JHEP Reports.2024; 6(1): 100911. CrossRef
Therapies for Cirrhotic Cardiomyopathy: Current Perspectives and Future Possibilities Hongqun Liu, Daegon Ryu, Sangyoun Hwang, Samuel S. Lee International Journal of Molecular Sciences.2024; 25(11): 5849. CrossRef
Novel approaches in the medical management of compensated cirrhosis Antonio Moreno-Loro, Álvaro Giráldez, Fernando Jiménez, Ignacio López-Bueno, Alberto Pérez-Ramírez, Manuel Romero-Gómez Expert Review of Gastroenterology & Hepatology.2024; 18(6): 239. CrossRef
Features of the course of hepatorenal syndrome in decompensated portal hypertension (case report) M.I. Tutchenko, D.V. Rudyk, M.S. Besedinskyi, S.L. Chub, Yu.V. Nerushchenko GASTROENTEROLOGY.2024; 58(2): 151. CrossRef
Microarray analysis demonstrates up-regulation of the endothelin-1 gene with compensatory down-regulation of the ETA receptor gene in human portal vein Nicola E. Owen, Thomas L. Williams, Janet J. Maguire, Rhoda E. Kuc, Emma E. Davenport, Anthony P. Davenport Bioscience Reports.2024;[Epub] CrossRef
The effect of propranolol on gastrointestinal motility and permeability in patients with cirrhosis and significant portal hypertension Elias Xirouchakis, Hariklia Kranidioti, Emilia Hadziyanni, Anastasia Kourikou, Christos Reppas, Maria Vertzoni, Nikolaos Papadopoulos, Melanie Deutsch, George Papatheodoridis, Spilios Manolakopoulos BMC Gastroenterology.2024;[Epub] CrossRef
Review article: diagnosis, pathophysiology and management of atrial fibrillation in cirrhosis and portal hypertension Bert Vandenberk, Mario H. Altieri, Hongqun Liu, Satish R. Raj, Samuel S. Lee Alimentary Pharmacology & Therapeutics.2023; 57(3): 290. CrossRef
Non-invasive tests-based risk stratification: Baveno VII and beyond Georg Semmler, Mathias Jachs, Mattias Mandorfer Clinical and Molecular Hepatology.2023; 29(1): 105. CrossRef
Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients” Yu Jun Wong, Sanchit Sharma, Giulia Tosetti, Xiaolong Qi, Massimo Primignani Clinical and Molecular Hepatology.2023; 29(1): 188. CrossRef
Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus‐related liver cirrhosis David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Nikolaos Pyrsopoulos, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(8): 1372. CrossRef
Dysregulated Calcium Handling in Cirrhotic Cardiomyopathy Sang Youn Hwang, Hongqun Liu, Samuel S. Lee Biomedicines.2023; 11(7): 1895. CrossRef
How to suspect the presence of high‐risk esophageal varices and when to start endoscopic surveillance in children with biliary atresia? Ujjal Poddar, Arghya Samanta, Moinak Sen Sarma, Basant Kumar, Richa Lal, Anshu Srivastava, Vijay Datta Upadhyaya, Surender Kumar Yachha, Ankur Mandelia Journal of Gastroenterology and Hepatology.2023; 38(9): 1610. CrossRef
Role of Galectin in Cardiovascular Conditions including Cirrhotic Cardiomyopathy Hongqun Liu, Sang-Youn Hwang, Samuel S. Lee Pharmaceuticals.2023; 16(7): 978. CrossRef
Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis Xinyi He, Zimo Zhao, Xi Jiang, Yan Sun Frontiers in Pharmacology.2023;[Epub] CrossRef
Portal vein thrombosis in cirrhosis: exploring the uncharted waters P Anirvan Journal of Gastroenterology and Hepatology.2023; 38(10): 1855. CrossRef
The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status Josip Stojic, Michał Kukla, Ivica Grgurevic Diagnostics.2023; 13(18): 2960. CrossRef
Nonselective beta-blockers may lead to stage 2 acute kidney injury and waitlist mortality in child class C cirrhosis Mason Lai, Cynthia Fenton, Jin Ge, Jessica Rubin, Jennifer C. Lai, Giuseppe Cullaro Hepatology Communications.2023;[Epub] CrossRef
Hepatorenal syndrome: Current concepts and future perspectives Chan-Young Jung, Jai Won Chang Clinical and Molecular Hepatology.2023; 29(4): 891. CrossRef
In severe alcohol‐related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL‐8 and micro‐RNAs Luke D. Tyson, Stephen Atkinson, Robert W. Hunter, Michael Allison, Andrew Austin, James W. Dear, Ewan Forrest, Tong Liu, Emma Lord, Steven Masson, Joao Nunes, Paul Richardson, Stephen D. Ryder, Mark Wright, Mark Thursz, Nikhil Vergis Alimentary Pharmacology & Therapeutics.2023; 58(11-12): 1217. CrossRef
Gut liver brain axis in diseases: the implications for therapeutic interventions Mengyao Yan, Shuli Man, Benyue Sun, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao Signal Transduction and Targeted Therapy.2023;[Epub] CrossRef
Changes of the bacterial composition in duodenal fluid from patients with liver cirrhosis and molecular bacterascites Jim Höppner, Sandra Krohn, Ellen H. A. van den Munckhof, René Kallies, Adam Herber, Katharina Zeller, Jan Tünnemann, Madlen Matz-Soja, Antonis Chatzinotas, Stephan Böhm, Albrecht Hoffmeister, Thomas Berg, Cornelius Engelmann Scientific Reports.2023;[Epub] CrossRef
Current knowledge about biomarkers of acute kidney injury in liver cirrhosis Han Ah Lee, Yeon Seok Seo Clinical and Molecular Hepatology.2022; 28(1): 31. CrossRef
Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy Hongqun Liu, Henry H. Nguyen, Ki Tae Yoon, Samuel S. Lee Frontiers in Network Physiology.2022;[Epub] CrossRef
Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database Hankil Lee, Beom Kyung Kim Journal of Gastroenterology and Hepatology.2022; 37(11): 2154. CrossRef
Prolonged QT Interval in Cirrhosis: Twisting Time? William Lee, Bert Vandenberk, Satish R. Raj, Samuel S. Lee Gut and Liver.2022; 16(6): 849. CrossRef
New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim Clinical and Translational Gastroenterology.2022; 13(12): e00542. CrossRef
Advances in cirrhotic cardiomyopathy Hongqun Liu, Ki Tae Yoon, Jing Zhang, Samuel S. Lee Current Opinion in Gastroenterology.2021; 37(3): 187. CrossRef
First
Prev
